Clinical trial
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell…
NCT00034541 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00034541 |
|---|---|
| Title | Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer |
| Official title | Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Carboplatin-Paclitaxel in Patients With Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | University of Colorado, Denver Greenwich Hospital Indiana University |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, paclitaxel, carboplatin |
| Enrollment | 32 |
| Start date | Dec 1, 2000 |
| Primary completion | May 1, 2003 |
| Completion | May 1, 2003 |
| First posted | May 1, 2002 |
| Last update posted | Apr 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: